"Freezing of gait treatment market to exhibit productive growth during the forecast period"
The global freezing of gait treatment market is growing effectually, expected to grow at a CAGR of 7.2%. Globally, increasing prevalence of Parkinson's disease has significantly increased the revenue of oral dopaminergic medications. FDA approval for new drugs, and promising pipeline products in the equipment and devices segment in the Parkinson's disease industry are driving the overall growth freezing of gait treatment market globally.
"Oral dopaminergic medication segment is expected to register higher growth by the end of 2030"
Levodopa (Inbrija™, by Acorda Therapeutics), along with carbidopa, remains the optimum standard of symptomatic treatment for (FoG) Parkinson disease orally. In Dec 2020, the U.S. FDA approved Inbrija™ for the alternating treatment of “OFF” incidents in people with Parkinson’s disease who are already treated with levodopa/carbidopa. It is a novel approach for the treatment of OFF periods in PD. Advanced pipeline products in the wearable and walking aid segment will show promising growth in near future. For e.g. In the CES 2020 conference in Las Vegas, a Chinese company named GYENNO showcased its gait aid equipment package, mainly helps to escape gait freeze in Parkinson’s patients. Additionally, Kyungpook National University showcased android based gait-aid system by using smart glasses with wearable sensors.
"Increasing admissions for freezing of gait in the hospital segment to witness a significant CAGR"
Increasing chronic Parkinson’s disease (PD) along with significant admissions in the hospitals internationally are notable factors expected for the growth of the market. According to FDA and other research studies, symptomatic and neuroprotective therapies are opted for PD in hospitals. Deep brain stimulation procedures along with helpful brain exercises are also adopted in the end user segment, showed promising results in recent time. Moreover, increasing elderly population along with increasing admissions is escalating the growth in the end-user segment. Moreover, lunch of new medications and equipment in the U.S. market and internationally along with increased funding for PD patient care for the administrations of freezing of gait treatment on a global scale will drive the growth during the forecast period.
"Increasing population, new FDA approval and the presence of top players holds the U.S. in dominant position"
In 2021, the U.S contributed maximum revenue share in the freezing of gait treatment market due to the rising prevalence of PD. Key prime factors include rising awareness about new medications and therapies, FDA approvals for new drugs, and rising PD care services along with enhanced reimbursement structure will drive the demand in near future. Emerging nations always suffer the burden of chronic diseases. Nevertheless, there is no significant treatment targeted towards freezing of gait in PD, but strong pipeline drugs and products along with the approval for levodopa will further enhance the growth on a global scale.
"Increased research and development with strong product pipelines in the developed regions"
Major players in the freezing of gait treatment market are Acorda Therapeutics, The Michael J. Fox Foundation, GYENNO, National University of Ireland, Galway (NUI Galway), Kyungpook National University, Republic of Korea, MedEXO Robotics, TABLE Teva Pharmaceuticals and others. Major organizations and research centers are developing progressive technologies with new technology expansion in the wearable and walking aids systems, electronic brain implants and other stimulators for freezing of gait treatment on a global scale.
The current report also comprehends qualitative and qualitative market valuation factors such as key market drivers, market trends, restraints and opportunities that gives a better market understanding of the overall freezing of gait treatment market. Additionally, the global report also comprises graphical representation of competitive landscape based on their market initiatives and strategies, product portfolio and business strengths.
Historical & Forecast Period
This study report represents analysis of each segment from 2022 to 2032 considering 2023 as the base year. Compounded Annual Growth Rate (CAGR) for each of the respective segments estimated for the forecast period of 2024 to 2032.
The current report comprises of quantitative market estimations for each micro market for every geographical region and qualitative market analysis such as micro and macro environment analysis, market trends, competitive intelligence, segment analysis, porters five force model, top winning strategies, top investment markets, emerging trends and technological analysis, case studies, strategic conclusions and recommendations and other key market insights.
Research Methodology
The complete research study was conducted in three phases, namely: secondary research, primary research, and expert panel review. key data point that enables the estimation of Freezing of Gait Treatment market are as follows:
Market forecast was performed through proprietary software that analyzes various qualitative and quantitative factors. Growth rate and CAGR were estimated through intensive secondary and primary research. Data triangulation across various data points provides accuracy across various analyzed market segments in the report. Application of both top down and bottom-up approach for validation of market estimation assures logical, methodical and mathematical consistency of the quantitative data.
| ATTRIBUTE | DETAILS |
|---|---|
| Research Period | 2022-2032 |
| Base Year | 2023 |
| Forecast Period | 2024-2032 |
| Historical Year | 2022 |
| Unit | USD Million |
| Segmentation | |
Treatment
| |
End User
| |
|
Region Segment (2022-2032; US$ Million)
|
Key questions answered in this report
